Cited by 132Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesChronic Obstructive Pulmonary Disease (COPD) Research

Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics

Open access
Smith, Stevens S.·2009·Archives of Internal Medicine

Abstract

BACKGROUND: Randomized efficacy clinical trials conducted in research settings may not accurately reflect the benefits of tobacco dependence treatments when used in real-world clinical settings. Effectiveness trials (eg, in primary care settings) are needed to estimate the benefits of cessation treatments in real-world use. METHODS: A total of 1346 primary care patients attending routine appointments were recruited by medical assistants in 12 primary care clinics. Patients were randomly assigned to 5 active pharmacotherapies: 3 monotherapies (nicotine patch, nicotine lozenge, and bupropion hydrochloride sustained release [SR]) and 2 combination therapies (patch + lozenge and bupropion SR + lozenge). Patients were referred to a telephone quit line for cessation counseling. Primary outcomes included 7-day point prevalence abstinence at 1 week, 8 weeks, and 6 months after quitting and number of days to relapse. RESULTS: Among 7128 eligible smokers (> or =10 cigarettes per day) attending routine primary care appointments, 1346 (18.9%) were enrolled in the study. Six-month abstinence rates for the 5 active pharmacotherapies were the following: bupropion SR, 16.8%; lozenge, 19.9%; patch, 17.7%; patch + lozenge, 26.9%; and bupropion SR + lozenge, 29.9%. Bupropion SR + lozenge was superior to all of the monotherapies (odds ratio, 0.46-0.56); patch + lozenge was superior to patch and bupropion monotherapies (odds ratio, 0.56 and 0.54, respectively). CONCLUSIONS: One in 5 smokers attending a routine primary care appointment was willing to make a serious quit attempt that included evidence-based counseling and medication. In this comparative effectiveness study of 5 tobacco dependence treatments, combination pharmacotherapy significantly increased abstinence compared with monotherapies. Provision of free cessation medications plus quit line counseling arranged in the primary care setting holds promise for assisting large numbers of smokers to quit. Trial Registration clinicaltrials.gov Identifier: NCT00296647.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archinternmed.2009.426

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Combining bupropion with NRT augments abstinence rates to 29%.

    “which are further augmented to 29% when the drug is combined with NRT [210, 234, 235].”

    From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [235]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [23]Silagy C Lancaster T Stead L Nicotine replacement therapy for smoking cessation (Cochrane Methodology Review) The Cochrane Library 4 2003 Chichester, UK John Wiley & Sons, Ltd

Cited by

Sorted by citations

Authors
Smith, S. S.
Affiliations
University of Wisconsin System (US)
Corresponding author
Smith, Stevens S.
Venue
Archives of Internal Medicine
Published
2009-12-14
Volume
169
Issue
22
Pages
2148
ISSN
0003-9926 (ISSN-L)
OpenAlex
W2137997423
Cited by
132
References
32
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 6 · 2022: 4 · 2021: 7 · 2020: 6 · 2019: 5 · 2018: 9 · 2017: 4 · 2016: 8 · 2015: 9 · 2014: 15 · 2013: 11 · 2012: 15
FWCI
9.53
Type
journal article
Language
en
Open access
Locations
  • Archives of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Wellcome Trust
  • National Institutes of Health (5k05ca139871-05)
  • National Institute on Drug Abuse (P50DA019706)
  • National Cancer Institute (K05 CA-139871, 1K05CA139871)
  • National Center for Research Resources (KL2RR025012)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
smoking cessation, tobacco dependence treatment, nicotine patch, nicotine lozenges, combination pharmacotherapy, abstinence rates, relapse, primary care, real-world effectiveness
MeSH terms
Humans, Primary Health Care, Smoking Cessation, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review